Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Charles V. Jackson is active.

Publication


Featured researches published by Charles V. Jackson.


Circulation | 1990

Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis.

Charles V. Jackson; V G Crowe; T.J Craft; J L Sundboom; B W Grinnell; J L Bobbitt; P J Burck; J.F Quay; Gerald F. Smith

LY210825, a recombinant tissue-type plasminogen activator (rt-PA), which contains the kringle-2 and serine protease functional domains of native tissue-type plasminogen activator, was previously produced by site-directed mutagenesis in a Syrian hamster cell line. We studied the thrombolytic potential of this molecule in a canine thrombosis model. Male hounds (16-22 kg) were anesthetized; a 2.0-cm segment of the left circumflex coronary artery (LCX) was isolated proximal to the first main branch, and the dogs were instrumented with an electromagnetic flow probe to measure coronary blood flow. An occlusive thrombus was formed after injury of the intimal surface of the LCX with an electrical current applied by a needle-tipped anode placed distal to the electromagnetic flow probe. After 1 hour of occlusion, either LY210825 or rt-PA was administered intravenously according to the following protocols: 1) a 1-hour infusion of either 0.25 mg/kg LY210825 or 0.4 mg/kg rt-PA, 2) single injections of 0.15-0.6 mg/kg LY210825, and 3) a single injection of 0.45 mg/kg LY210825 and a 3-hour infusion of 1.0 or 1.7 mg/kg rt-PA. Plasma half-lives of LY210825 and rt-PA were 58 +/- 7 and 3.3 +/- 0.3 minutes, respectively. LY210825 produced more rapid reperfusion of the LCX than did rt-PA. In the third study, 90% of the rt-PA-treated vessels reoccluded within 1 hour after cessation of drug, whereas only 25% of the LY210825-treated vessels reoccluded during a 4-hour washout period. There were significant, but relatively small, reductions produced by both plasminogen activators on plasma fibrinogen and plasminogen (25-35% decreases). Because of its longer plasma half-life, LY210825 could be administered intravenously as a single injection. In a canine model of coronary artery thrombosis, LY210825 was a more effective thrombolytic agent than was rt-PA.


Journal of Pharmacology and Experimental Therapeutics | 2000

Pharmacological Profile of Recombinant, Human Activated Protein C (LY203638) in a Canine Model of Coronary Artery Thrombosis

Charles V. Jackson; Blanche D. Bailey; Timothy J. Shetler


Journal of Pharmacology and Experimental Therapeutics | 1992

Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis.

Charles V. Jackson; V G Crowe; J D Frank; H C Wilson; W J Coffman; B G Utterback; J A Jakubowski; G F Smith


Seminars in Thrombosis and Hemostasis | 1996

A family of arginal thrombin inhibitors related to efegatran

Gerald F. Smith; Robert Theodore Shuman; Trelia J. Craft; Donetta S. Gifford; Kenneth D. Kurz; Noel D. Jones; Nickolay Y. Chirgadze; Robert Bell Hermann; William J. Coffman; George E. Sandusky; Eiry Roberts; Charles V. Jackson


Archive | 1998

Methods for treating vascular disorders using activated protein C

Brian W. Grinnell; Daniel C. Howey; Charles V. Jackson


Circulation | 1996

Antithrombotic Assessment of the Effects of Combination Therapy With the Anticoagulants Efegatran and Heparin and the Glycoprotein IIb-IIIa Platelet Receptor Antagonist 7E3 in a Canine Model of Coronary Artery Thrombosis

Timothy J. Shetler; V. Gail Crowe; Blanche D. Bailey; Charles V. Jackson


Archive | 1990

Method of treating thromboembolic disorders by administration of diglycosylated t-pa variants

Philip J. Burck; Charles V. Jackson; Gerald F. Smith


Journal of Pharmacology and Experimental Therapeutics | 1992

Comparison of the thrombolytic activity of the novel plasminogen activator, LY210825, to anisoylated plasminogen-streptokinase activator complex in a canine model of coronary artery thrombolysis.

Charles V. Jackson; J D Frank; T J Craft; J L Sundboom; G F Smith


Thrombosis Research | 1998

Intravenous administration of the glycoprotein IIb-IIIa receptor antagonist 7E3 induces reperfusion of an acute thrombotic occlusion of the canine coronary artery

Timothy J. Shetler; Blanche D. Bailey; Joseph A. Jakubowski; Charles V. Jackson


Archive | 1992

Prevention of reocclusion by a thrombin inhibitor (LY282056)

Robert Theodore Shuman; Robert B. Rothenberger; Charles S. Campbell; Gerald F. Smith; Charles V. Jackson; Kenneth D. Kurz; Paul David Gesellchen

Collaboration


Dive into the Charles V. Jackson's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge